Enakshi D Sunassee, Riley J Deutsch, Victoria W D'Agostino, Pol Castellano-Escuder, Elizabeth A Siebeneck, Olga Ilkayeva, Brian T Crouch, Megan C Madonna, Jeffrey Everitt, James V Alvarez, Gregory M Palmer, Matthew D Hirschey, Nirmala Ramanujam
Fewer than 20% of triple-negative breast cancer patients experience long-term responses to mainstay chemotherapy. Resistant tumor subpopulations use alternative metabolic pathways to escape therapy, survive, and eventually recur. Here, we show in vivo, longitudinal metabolic reprogramming in residual disease and recurrence of triple-negative breast cancer xenografts with varying sensitivities to the chemotherapeutic drug paclitaxel. Optical imaging coupled with metabolomics reported an increase in non-glucose-driven mitochondrial metabolism and an increase in intratumoral metabolic heterogeneity during regression and residual disease in resistant MDA-MB-231 tumors...
April 5, 2024: Science Advances